#Canada #Vancouver #Bold Therapeutics #BOLD-100 #OIPN

Bold Therapeutics Showcases Breakthrough in Neuropathy Prevention

At the recent AACR Annual Meeting 2025, Bold Therapeutics Inc. presented groundbreaking data regarding their innovative treatment, BOLD-100, which has showcased unique neuroprotective abilities against oxaliplatin-induced peripheral neuropathy (OIPN). This important finding was shared by Dr. Mark Bazett, the company’s Sr. Director of Preclinical Development, during a late-breaking poster session attended by industry leaders and researchers alike.

Understanding Oxaliplatin-Induced Peripheral Neuropathy

Oxaliplatin, a common chemotherapeutic agent used for treating various forms of gastrointestinal cancers, often leads to debilitating side effects, particularly in the form of OIPN. This situation poses significant challenges for patients as it can adversely affect their quality of life and hinder their treatment progress. Thus, any potential remedy that could alleviate these symptoms is of paramount interest in the oncology field.

The Findings from Bold Therapeutics

In their global Phase 1b/2a trial, identified as BOLD-100-001 (NCT04421820), Bold Therapeutics enrolled 109 patients diagnosed with advanced gastrointestinal cancers, including colorectal cancer, gastric cancer, and pancreatic cancer. The trial revealed encouraging efficacy data while also noting a marked decrease in the incidence and severity of OIPN among those treated with BOLD-100 in combination with FOLFOX (5-fluorouracil, oxaliplatin, leucovorin). This contrasts starkly with the higher historical benchmarks of neuropathy rates usually observed in patients receiving FOLFOX alone.

Through direct feedback from trial investigators, it was clear that patients treated with BOLD-100 exhibited significantly lower rates of neuropathy, with many highlighting the robust performance even among those with older and more severe conditions. These promising results prompted further investigation into BOLD-100's neuroprotective mechanisms, culminating in a preclinical rat model study that effectively mimicked the OIPN symptoms.

Preclinical Evidence and Continued Research

In this preclinical study, rats were administered oxaliplatin and subsequently treated with BOLD-100 over a period of 17 days. The outcomes revealed a conclusive reduction in neuropathic pain in the test subjects treated with BOLD-100 - a revelation that was critical in substantiating the clinical findings previously observed.

Once the treatment was halted, symptoms of neuropathy returned swiftly, signaling the crucial role BOLD-100 plays in maintaining pain relief. As such, Bold Therapeutics is not just stopping here; ongoing research aims to explore if BOLD-100 can also mitigate side effects from other neuropathy-inducing agents, including taxanes.

Implications for Future Cancer Treatment

The implications of these findings are substantial. The potential of BOLD-100 to help patients not only improve their overall outcomes during cancer treatment but also allow them to complete chemotherapy cycles without reductions in dosage or premature treatment discontinuation can be revolutionary. This is especially significant as it facilitates a more positive experience for patients, reducing their pain and sensory issues progressively associated with cancer therapies.

Looking Ahead

Bold Therapeutics is now actively enrolling FOLFOX-naïve second-line metastatic colorectal cancer patients in a multinational randomized clinical study, comparing the effects of FOLFOX alone versus FOLFOX combined with BOLD-100. Through this study, the company aims to further establish BOLD-100's potential as a transformative therapy, not just for colorectal cancer, but for broader oncology applications.

The dedication to connecting and collaborating with investors, key opinion leaders, and clinical partners underscores the ambitious trajectory that Bold Therapeutics is embarking upon. This commitment not only showcases the innovative spirit of Bold Therapeutics but also reflects a promising future for patients facing these challenging conditions.

For additional details on how BOLD-100 could transform cancer care, visit Bold Therapeutics' official website.